Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2007

View Archived Issues

Targeting TRPV1 for the treatment of type 1 diabetes

Sirolimus to be tested in clinical trial for ALPS / News in Context

Novartis reports positive preclinical results of novel Nurr1 activator

Targepeutics developing targeted molecular therapies for cancer

NEOSH-101 increases hair growth significantly in men with androgenetic alopecia

Refrigerated formulation of FluMist receives FDA approval

Depression and anxiety compound TC-2216 begins phase I trial

New phase II study evaluates R-788 in ITP

Interim analysis clears pivotal study of pralatrexate to continue

Phase II/III pain program outlined for Anesiva's 4975

Alkermes and Lilly sign manufacturing agreement for AIR Inhaled Insulin

Genentech and Seattle Genetics sign worldwide license agreement for SGN-40

Bayer and Berlex combine businesses in Canada

Boehringer Ingelheim and Ablynx to develop Nanobodies for Alzheimer's

New phase II trial studies nemonoxacin for CAP

ZEN-012 begins phase I study in solid tumors and lymphoma

Patents disclose therapeutic agents for schizophrenia, depression and other psychological disorders

Novel antiinfective agents disclosed in recent AstraZeneca and Novozymes patents

New vitamin D3 receptor agonists prepared and tested at Chugai

CAT grants iCo license to CAT-213

Pierre Fabre acquires UCB's OTC business in certain countries

deCODE genetics updates development programs

European approval for once-weekly NeoRecormon

Orphan drug designation for PV-10 in metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...